Palmer Barton W, Harmell Alexandrea L, Dunn Laura B, Kim Scott Y, Pinto Luz L, Golshan Shahrokh, Jeste Dilip V
a Veterans Affairs San Diego Healthcare System , San Diego , California , USA.
b Veterans Medical Research Foundation , San Diego , California , USA.
Clin Gerontol. 2018 Jan-Feb;41(1):20-32. doi: 10.1080/07317115.2017.1373177. Epub 2017 Nov 28.
Optimizing the research consent process simultaneously fosters respect for autonomy and protection of those with diminished capacity for autonomy. This study evaluated the effectiveness of an enhanced research consent procedure, employing multimedia disclosure and corrective feedback, in improving decisional capacity among 114 people with mild-to-moderate Alzheimer's disease (AD) and 134 non-psychiatric comparison (NC) subjects.
Participants were randomized to consent type (routine versus enhanced) and protocol type (lower versus higher risk). Outcomes included a 5-item questionnaire assessing immediate comprehension, MacArthur Competence Assessment Tool for Clinical Research assessing four components of decision-making capacity, and categorical decisional capacity (based on a cut-score established in reference to expert judgments for a subset of participants).
There was no significant effect of the enhanced consent procedure, relative to routine consent, on immediate comprehension or decisional capacity.
Multimedia tools do not appear to be the solution to better consent for AD research.
Given the ethical primacy of informed consent and issues of justice for impaired populations who might be harmed by an absence of research-based treatment advances, continued search for ways to more meaningfully engage people with AD in the consent or assent process is warranted.
优化研究同意程序既能促进对自主性的尊重,又能保护自主性能力减弱的人群。本研究评估了一种强化研究同意程序(采用多媒体披露和纠正反馈)在提高114名轻度至中度阿尔茨海默病(AD)患者和134名非精神科对照(NC)受试者决策能力方面的有效性。
参与者被随机分为同意类型(常规与强化)和方案类型(低风险与高风险)。结果包括一份评估即时理解能力的5项问卷、评估决策能力四个组成部分的麦克阿瑟临床研究能力评估工具,以及分类决策能力(基于参考一部分参与者的专家判断确定的得分标准)。
相对于常规同意,强化同意程序对即时理解能力或决策能力没有显著影响。
多媒体工具似乎并非改善AD研究同意情况的解决方案。
鉴于知情同意的伦理首要性以及对于可能因缺乏基于研究的治疗进展而受到伤害的受损人群的公平问题,有必要继续寻找让AD患者更有意义地参与同意或赞同过程的方法。